MedTrace Logo

Special Drug Use Surveillance of Irribow in Female Patients

NCT02612649 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 793

Last updated 2024-10-21

No results posted yet for this study

Summary

The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.

Conditions

  • Diarrhea-predominant Irritable Bowel Syndrome

Interventions

DRUG

Ramosetron

Oral

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Inc

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612649 on ClinicalTrials.gov